HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.4%

Neg 0% Neu 90.4% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $55 price target.